Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double-blind, placebo-controlled, parallel-group trial to assess clinical efficacy and safety of danegaptide in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention

Next Previous
X
Search
Trial Profile

A randomised, double-blind, placebo-controlled, parallel-group trial to assess clinical efficacy and safety of danegaptide in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Danegaptide (Primary)
  • Indications Myocardial infarction; Myocardial reperfusion injury
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Zealand Pharma

    • Most Recent Events

    • 30 Mar 2023 Results assessing if scar core mass, border zone (BZ) mass, and BZ channels are risk markers for subsequent ventricular arrhythmia (VA) in ST-segment elevation myocardial infarction published in the Europace
    • 02 Mar 2016 According to a Zealand Pharma media release, the company announced top line results from this phase II Proof-of-Concept trial of danegaptide for the protection against cardiac reperfusion injuries in patients with an acute myocardial infarction.
    • 02 Mar 2016 Primary endpoint [Myocardial Salvage Index [ Time Frame: 3 months ] [ Designated as safety issue: No ] Myocardial Salvage Index as assessed by MRI and calculated as the difference between myocardial volume at risk and final infarct size in relation to myocardial volume at riskhas not been met. (Myocardial Salvage Index)] has not been met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top